637 related articles for article (PubMed ID: 22675168)
1. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
[TBL] [Abstract][Full Text] [Related]
2. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
3. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
4. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
5. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R
Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960
[TBL] [Abstract][Full Text] [Related]
6. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study.
White C; Bakhiet S; Bates M; Keegan H; Pilkington L; Ruttle C; Sharp L; O' Toole S; Fitzpatrick M; Flannelly G; O' Leary JJ; Martin CM
Cytopathology; 2016 Aug; 27(4):269-76. PubMed ID: 26932360
[TBL] [Abstract][Full Text] [Related]
7. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
8. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.
Luttmer R; Dijkstra MG; Snijders PJ; Berkhof J; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; van Baal WM; Graziosi PG; Quint WG; Spruijt JW; van Dijken DK; Heideman DA; Meijer CJ
Mod Pathol; 2016 Aug; 29(8):870-8. PubMed ID: 27150161
[TBL] [Abstract][Full Text] [Related]
9. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
10. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
11. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R;
Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
15. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG
Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
[TBL] [Abstract][Full Text] [Related]
16. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
17. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J
Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL).
Frega A; Pavone M; Sesti F; Leone C; Bianchi P; Cozza G; Colombrino C; Lukic A; Marziani R; De Sanctis L; Delli Carpini G; Caserta D; Ciavattini A
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10672-10677. PubMed ID: 31858534
[TBL] [Abstract][Full Text] [Related]
19. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
Peeters E; Wentzensen N; Bergeron C; Arbyn M
Cancer Cytopathol; 2019 Mar; 127(3):169-180. PubMed ID: 30811902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
